Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe
The Omnipod 5 Automated Insulin Delivery System is now commercially available in
Omnipod 5 is now available with both Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 Continuous Glucose Monitoring (CGM) sensor compatibility. Indicated for individuals aged two years and older with type 1 diabetes, Omnipod 5 is the first and only tubeless automated insulin delivery (AID) system integrated with both leading CGM sensor brands.
“We are excited to bring our flagship Omnipod 5 AID System to more people across Europe,” said Patrick Crannell, Insulet Senior Vice President and International General Manager. “Following our successful launches of Omnipod 5 in the
Omnipod is recognized as the number one insulin pump for new pump users in
"I can’t wait to get my Omnipod 5 so I can think less about diabetes,” said Lina, a 45-year-old resident of
Sensor integration with Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 allows many users to benefit from Omnipod 5 with their sensor of choice. It also gives prescribers more flexibility when recommending a sensor for their patients, making it fast and easy to start AID therapy with Omnipod 5.
“Omnipod 5 with two sensor choices is going to change lives for people living with type 1 diabetes in
To learn more or to get started, visit the Omnipod website.
1 Omnipod was the most frequently chosen pump in the past year among people new to an insulin pump in a survey conducted by dQ&A across
2
3 The Pod has an IP28 rating for up to 7.6 meters (25 feet) for 60 minutes. The Omnipod® 5 controller is not waterproof. The Dexcom G6 sensor and transmitter are water-resistant and may be submerged under 2.4 meters (8 feet) of water for up to 24 hours without failure when properly installed. The FreeStyle Libre 2 Plus sensor is water-resistant in up to 1 meter (3 feet) of water. Do not immerse longer than 30 minutes.
4 Sherr JL, et al. Diabetes Care (2022). Study in 80 people with type 1 diabetes (T1D) aged 2 - 5.9 years involving two weeks standard diabetes therapy followed by three months Omnipod 5 use in Automated Mode.
5 Brown et al. Diabetes Care (2021). Study in 240 people with T1D aged 6 - 70 years involving two weeks standard diabetes therapy followed by three months Omnipod 5 use in Automated Mode.
6 Forlenza GP et al. Diabetes Technology & Therapeutics (2024). Real-World Evidence of Omnipod 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in
©2025 Insulet Corporation. Omnipod and Podder are registered trademarks of Insulet Corporation. All rights reserved. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. Dexcom is a registered trademark of Dexcom, Inc. and used with permission. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113217259/en/
Investor Relations:
June Lazaroff
Senior Director, Investor Relations
(978) 600-7718
jlazaroff@insulet.com
Media:
Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com
Source: Insulet Corporation